Explore

Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases
Trendline Trendline
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding
Trendline Trendline
Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments
Trendline Trendline
Leonardo DRS to Acquire Raft, Enhancing AI and Data Fusion Capabilities

Leonardo DRS to Acquire Raft, Enhancing AI and Data Fusion Capabilities

Leonardo DRS to Acquire Raft, Enhancing AI and Data Fusion Capabilities
Trendline Trendline
Legora Acquires Wexler to Enhance Legal Fact Intelligence Capabilities

Legora Acquires Wexler to Enhance Legal Fact Intelligence Capabilities

Legora Acquires Wexler to Enhance Legal Fact Intelligence Capabilities
Trendline Trendline
Doctronic Acquires Summer Health to Enhance Pediatric Care with AI Integration

Doctronic Acquires Summer Health to Enhance Pediatric Care with AI Integration

Doctronic Acquires Summer Health to Enhance Pediatric Care with AI Integration
Trendline Trendline
Carlyle Group Acquires Secturion Systems to Enhance Data Protection Capabilities

Carlyle Group Acquires Secturion Systems to Enhance Data Protection Capabilities

Carlyle Group Acquires Secturion Systems to Enhance Data Protection Capabilities
Trendline Trendline
Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences

Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences

Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences
Trendline Trendline
Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio

Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio

Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio
Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment